Barcelona (ACN).- Researchers at the Autonomous University of Barcelona (UAB), the Council of Scientific Researches (CSIC) and the University of Barcelona (UB) have created ASS234, a molecule that works in different parts of the brain simultaneously and is useful for creating a new medicine in the treatment of Alzheimer's disease. The molecule inhibits the secretion of the B-amiloide protein, which is a contributory factor in the disease.
The research project, led by Mercedes Unzeta, José Luis Marco and F. Javier Luque, has been looking for a way to target different areas of the brain at the same time, unlike current medicines that just work in one part of the brain, even though the damage is more extensive throughout the brain.
ASS234 is a hybrid of two known molecules. Donepezil, the first of these, is used in the treatment of Alzheimer's disease and the second, PF9601N, inhibits the secretion of the B-amiloide protein and has a neuro-protective effect in relation to Parkinson’s disease. To sum up, the new molecule has a protective effect while it is stimulating neuronal transmission. Moreover, other researchers at the Cajal Institute in CSIC and the University of Lodz (Poland) have tested ASS234 in rats, and it has improved their memory.
According to Drs Mercedes Unzeta and Marcos Contelles in Barcelona, ASS234 is a derivative of Donepezil and has some “potential pharmacological effects that could make it the most effective treatment for fighting Alzheimer's disease. The research has recently been published in the Journal of Medicinal Chemistry.